Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

LOS ANGELES, June 25 (Reuters) - Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S ...

Wegovy will now be the GLP-1 weight loss drug of choice under plans that are managed by CVS Caremark. If they stay on Zepbound for their GLP-1 weight loss treatment, they will have to pay full ...

From Philly and the Pa. suburbs to South Jersey and Delaware, what would you like WHYY News to cover? Let us know! Ever since blockbuster weight-loss drugs like Wegovy and Zepbound went mainstream, ...

Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk's Wegovy.

Zepbound joins the GLP-1 ranks for weight loss with Wegovy and Saxenda. Tirzepatide is the main ingredient in Zepbound, approved label for weight management, and Mounjaro, the brand name approved ...

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.

Novo Nordisk’s arch-rival in the obesity market is Eli Lilly LLY. NVO’s Ozempic and Wegovy face strong competition from Lilly’s tirzepatide medicines, Mounjaro (T2D) and Wegovy (obesity).

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.